Neuroinflammation in Schizophrenia
Downloads
Schizophrenia is a chronic debilitating mental illness. In many aspects, the neuropathology of schizophrenia is closely associated with neuroinflammation, especially microglial activation. Microglial hyperactivity, which is characterized by the predominant release of proinflammatory cytokines serves as the basis of the neuroinflammation hypothesis in schizophrenia. The enhanced inflammatory induce neuronal susceptibility to oxidative stress and trigger, glutamatergic synaptic dysregulation, especially in the mesolimbic and mesocortical pathways. Many in vitro studies, in vivo animal evidence, post-mortem examinations, neuroimaging evaluations with Positron Emission Tomography (PET), anti-inflammatory and antipsychotic use converge upon the central role of microglial activation and proinflammatory cytokines as common of features schizophrenia.
M. D. Benjamin J. Sadock, M.D. Virginia A. Sadock, M.D. Pedro Ruiz, Ed., "Schizophrenia and other Psychotic Disorder,” in Kaplan & Sadocks's Comprehensive Textbook of Psychiatry, Tenth., New York: Wolters Kluwer, 2017, p. Schizophrenia and other Psychotic Disorder.
et al Khandaker GM., Neuroinflammation and Schizophrenia, 44 th edit. Cambridge UK: "Springer Nature Switzerland AG 2020, 2020.
P. F. Buckley, "Neuroinflammation and Schizophrenia,” Curr. Psychiatry Rep., vol. 21, no. 8, pp. 19–21, 2019, doi: 10.1007/s11920-019-1050-z.
N. Müller, E. Weidinger, B. Leitner, and M. J. Schwarz, "The role of inflammation in schizophrenia,” Front. Neurosci., vol. 9, no. OCT, 2015, doi: 10.3389/fnins.2015.00372.
A. G. Dietz, S. A. Goldman, and M. Nedergaard, "Glial cells in schizophrenia: a unified hypothesis,” The Lancet Psychiatry, vol. 7, no. 3, pp. 272–281, 2020, doi: 10.1016/S2215-0366(19)30302-5.
L. J. De Picker, M. Morrens, S. A. Chance, and D. Boche, "Microglia and brain plasticity in acute psychosis and schizophrenia illness course: A meta-review,” Front. Psychiatry, vol. 8, no. NOV, pp. 1–14, 2017, doi: 10.3389/fpsyt.2017.00238.
L. E. Laskaris et al., "Microglial activation and progressive brain changes in schizophrenia,” Br. J. Pharmacol., vol. 173, no. 4, pp. 666–680, 2016, doi: 10.1111/bph.13364.
I. López-González, R. Pinacho, È. Vila, A. Escanilla, I. Ferrer, and B. Ramos, "Neuroinflammation in the dorsolateral prefrontal cortex in elderly chronic schizophrenia,” Eur. Neuropsychopharmacol., vol. 29, no. 3, pp. 384–396, 2019, doi: 10.1016/j.euroneuro.2018.12.011.
P. S. Bloomfield et al., "Microglial activity in people at ultra high risk of psychosis and in schizophrenia: An [11C]PBR28 PET brain imaging study,” Am. J. Psychiatry, vol. 173, no. 1, pp. 44–52, 2016, doi: 10.1176/appi.ajp.2015.14101358.
T. R. Marques et al., "Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies,” Psychol. Med., vol. 49, no. 13, pp. 2186–2196, 2019, doi: 10.1017/S0033291718003057.
M. Norbert, "Inflammation in Schizophrenia : Pathogenetic Aspects and Therapeutic Considerations,” no. April, pp. 1–10, 2018, doi: 10.1093/schbul/sby024.
C. C. Watkins and S. Ramsay, "Clinical studies of neuroin fl ammatory mechanisms in schizophrenia,” 2015, doi: 10.1016/j.schres.2015.07.018.
S. Najjar, S. Pahlajani, V. De Sanctis, J. N. H. Stern, A. Najjar, and D. Chong, "Neurovascular Unit Dysfunction and Blood–Brain Barrier Hyperpermeability Contribute to Schizophrenia Neurobiology: A Theoretical Integration of Clinical and Experimental Evidence,” Front. Psychiatry, vol. 8, no. May, 2017, doi: 10.3389/fpsyt.2017.00083.
B. Pedraz-Petrozzi, O. Elyamany, C. Rummel, and C. Mulert, "Effects of inflammation on the kynurenine pathway in schizophrenia - A systematic review,” J. Neuroinflammation, vol. 17, no. 1, pp. 1–17, 2020, doi: 10.1186/s12974-020-1721-z.
"Psychosis and Schizophrenia,” in Stahl's Essential psychopharmacology, 2013.
S. A. Kusuma and Y. Setiawati, "LITERATURE REVIEW : COGNITIVE DYSFUNCTION IN SCHIZOPHRENIA,” vol. 9.
J. Kindler et al., "Dysregulation of kynurenine metabolism is related to proinflammatory cytokines, attention, and prefrontal cortex volume in schizophrenia,” Mol. Psychiatry, vol. 25, no. 11, pp. 2860–2872, 2020, doi: 10.1038/s41380-019-0401-9.
H. Noyan et al., "Association of the kynurenine pathway metabolites with clinical, cognitive features and IL-1β levels in patients with schizophrenia spectrum disorder and their siblings,” Schizophr. Res., vol. 229, pp. 27–37, 2021, doi: 10.1016/j.schres.2021.01.014.
E. Nanou and W. A. Catterall, "Calcium Channels, Synaptic Plasticity, and Neuropsychiatric Disease,” Neuron, vol. 98, no. 3, pp. 466–481, 2018, doi: 10.1016/j.neuron.2018.03.017.
C. Fourrier, G. Singhal, and B. T. Baune, "Neuroin fl ammation and cognition across psychiatric conditions,” pp. 1–12, 2019, doi: 10.1017/S1092852918001499.
Copyright (c) 2021 Feytie Magda Mawey, Azimatul Karimah, Erlyn Limoa, Muhammad Nazmuddin
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. Copyright of this journal is possession of the Author, by the knowledge of the Editorial Board and Journal Manager, while the moral right of the publication belongs to the author.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The articles are published under a Creative Commons Attribution Share-Alike (CC BY-SA) license. Many research funding bodies prefer the CC BY-SA license because it allows for maximum dissemination and re-use of open access materials. Users are free to share (copy, distribute, and transmit) and remix (adapt) the contribution under this license, including for commercial purposes, as long as they attribute the contribution in the manner specified by the author or licensor.
